Developing Dual-Acting Gene Therapy to Combat Geographic Atrophy & Prevent AMD Progression
Time: 2:00 pm
day: Conference Day Two
Details:
- Engineering bi-functional IKAR-001 gene therapy to provide synergistic complement targeting, inflammation control, and neuroprotection for GA treatment
- Utilizing advanced preclinical models to validate therapeutic efficacy and establish proof-of-concept for dual-protein approach
- Outline the role of PEDF and sCD46 in wet-AMD to emphasis the effectiveness of IKAR-001 gene therapy technology
